FDA Inspection 735266 — Radnostix

Radnostix — FEI 3003350319

The FDA completed an inspection of Radnostix on July 22, 2011 in Idaho Falls, ID. The inspection was classified OAI (Official Action Indicated — objectionable conditions were found and regulatory action is recommended). 20 citations were issued during this inspection. Product area: Drugs.

Inspection Details

Classification
Official Action Indicated (OAI) (OAI)
End Date
July 22, 2011
Fiscal Year
2011
Product Type
Drugs
Project Area
Unapproved and Misbranded Drugs
Location
Idaho Falls, ID (United States)

Citations

IDCFRDescription
109821 CFR 211.22(c)Approve or reject procedures or specs
113321 CFR 211.25(a)GMP Training Frequency
121521 CFR 211.67(b)Written procedures not established/followed
122721 CFR 211.67(c)Cleaning/maintenance records not kept
136121 CFR 211.100(a)Absence of Written Procedures
145021 CFR 211.113(a)Procedures for non-sterile drug products
149521 CFR 211.122(a)Written procedures describing in detail
150721 CFR 211.122(f)Gang printed labeling
154021 CFR 211.125(a)Strict control not exercised over labeling issued
178721 CFR 211.80(a)Procedures To Be in Writing
180121 CFR 211.84(a)Components withheld from use pending release
183321 CFR 211.84(d)(1)Identity Testing of Each Component
188321 CFR 211.165(a)Testing and release for distribution
191421 CFR 211.166(a)Lack of written stability program
202621 CFR 211.192Quality control unit review of records
431421 CFR 211.84(d)(2)Reports of Analysis (Components)
433621 CFR 211.150Written distribution procedure
435221 CFR 211.160(b)(4)Calibration - at intervals, written program, remedial action
437221 CFR 211.188(b)(8)Labeling control records including specimens or copies
440021 CFR 211.186(b)(8)Description of containers, labels, et. al.